{"id":50328,"date":"2022-06-27T12:44:32","date_gmt":"2022-06-27T11:44:32","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=50328"},"modified":"2022-06-27T12:44:32","modified_gmt":"2022-06-27T11:44:32","slug":"stephen-ansell-asco-2022","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/lymphoma\/conference-hub\/stephen-ansell-asco-2022\/","title":{"rendered":"Stephen Ansell, ASCO 2022: Challenges and unmet treatment needs in Hodgkin lymphoma"},"content":{"rendered":"
Hodgkin lymphoma is a challenging disease and a cure, with current therapy, is possible in some but not all patients. Dr Stephen Ansell <\/b>(Mayo Clinic, Rochester, MN, USA) discusses these challenges and the unmet needs in the treatment of Hodgkin lymphoma.\u00a0<\/span><\/p>\n Dr Stephen Ansell presented an abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1’ (Abstract number 7503<\/a>)\u00a0at the ASCO<\/a> annual meeting,<\/span>\u00a0June 3-7, 2022.<\/span><\/p>\n Question<\/strong>:<\/span><\/p>\n 1. What are the challenges and unmet needs in the frontline treatment of Hodgkin lymphoma? (0:16)<\/p>\n Disclosures<\/strong>: Stephen Ansell has received grant\/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.<\/span><\/p>\n Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/span><\/p>\n